59.92
-1.07 (-1.75%)
| Previous Close | 60.99 |
| Open | 62.00 |
| Volume | 1,399,727 |
| Avg. Volume (3M) | 1,262,909 |
| Market Cap | 1,778,906,624 |
| Price / Earnings (Forward) | 188.68 |
| Price / Sales | 3.86 |
| Price / Book | 6.89 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2026 |
| Profit Margin | -11.69% |
| Operating Margin (TTM) | -5.22% |
| Diluted EPS (TTM) | -1.39 |
| Quarterly Revenue Growth (YOY) | 39.60% |
| Total Debt/Equity (MRQ) | 44.61% |
| Current Ratio (MRQ) | 3.25 |
| Operating Cash Flow (TTM) | -1.90 M |
| Levered Free Cash Flow (TTM) | 17.79 M |
| Return on Assets (TTM) | -1.84% |
| Return on Equity (TTM) | -16.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | GeneDx Holdings Corp. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | -4.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | -0.40 |
|
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 12.56% |
| % Held by Institutions | 102.71% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Oracle Investment Management Inc | 31 Dec 2025 | 884,654 |
| Zweig-Dimenna Associates Llc | 31 Mar 2026 | 689,290 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FEELEY KEVIN | - | 58.47 | -4,995 | -297,291 |
| STUELAND KATHERINE | - | 58.47 | -14,140 | -841,345 |
| Aggregate Net Quantity | -19,135 | |||
| Aggregate Net Value ($) | -1,138,637 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 58.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| STUELAND KATHERINE | Officer | 16 Jun 2026 | Sell (-) | 10,501 | 60.60 | 636,361 |
| STUELAND KATHERINE | Officer | 16 Jun 2026 | Option execute | 18,750 | - | - |
| FEELEY KEVIN | Officer | 16 Jun 2026 | Sell (-) | 3,729 | 60.60 | 225,977 |
| FEELEY KEVIN | Officer | 16 Jun 2026 | Option execute | 7,197 | - | - |
| STUELAND KATHERINE | Officer | 09 Jun 2026 | Sell (-) | 3,639 | 56.33 | 204,985 |
| STUELAND KATHERINE | Officer | 09 Jun 2026 | Option execute | 6,546 | - | - |
| FEELEY KEVIN | Officer | 09 Jun 2026 | Sell (-) | 1,266 | 56.33 | 71,314 |
| FEELEY KEVIN | Officer | 09 Jun 2026 | Option execute | 2,462 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |